Retrospective cohort study investigating synergism of air pollution and corticosteroid exposure in promoting cardiovascular and thromboembolic events in older adults.

Josey, Kevin; Nethery, Rachel; Visaria, Aayush; Bates, Benjamin; Gandhi, Poonam; Parthasarathi, Ashwaghosha; Rua, Melanie; Robinson, David et al. · BMJ Open · 2023

retrospective_cohort · Level III

Where this comes from

Abstract

To evaluate the synergistic effects created by fine particulate matter (PM<sub>2.5</sub>) and corticosteroid use on hospitalisation and mortality in older adults at high risk for cardiovascular thromboembolic events (CTEs). A retrospective cohort study using a US nationwide administrative healthcare claims database. A 50% random sample of participants with high-risk conditions for CTE from the 2008-2016 Medicare Fee-for-Service population. Corticosteroid therapy and seasonal-average PM<sub>2.5</sub>. Incidences of myocardial infarction or acute coronary syndrome (MI/ACS), ischaemic stroke or transient ischaemic attack, heart failure (HF), venous thromboembolism, atrial fibrillation and all-cause mortality. We assessed additive interactions between PM<sub>2.5</sub> and corticosteroids using estimates of the relative excess risk due to interaction (RERI) obtained using marginal structural models for causal inference. Among the 1 936 786 individuals in the high CTE risk cohort (mean age 76.8, 40.0% male, 87.4% white), the mean PM<sub>2.5</sub> exposure level was 8.3±2.4 µg/m<sup>3</sup> and 37.7% had at least one prescription for a systemic corticosteroid during follow-up. For all outcomes, we observed increases in risk associated with corticosteroid use and with increasing PM<sub>2.5</sub> exposure. PM<sub>2.5</sub> demonstrated a non-linear relationship with some outcomes. We also observed evidence of an interaction existing between corticosteroid use and PM<sub>2.5</sub> for some CTEs. For an increase in PM<sub>2.5</sub> from 8 μg/m<sup>3</sup> to 12 μg/m<sup>3</sup> (a policy-relevant change), the RERI of corticosteroid use and PM<sub>2.5</sub> was significant for HF (15.6%, 95% CI 4.0%, 27.3%). Increasing PM<sub>2.5</sub> from 5 μg/m<sup>3</sup> to 10 μg/m<sup>3</sup> yielded significant RERIs for incidences of HF (32.4; 95% CI 14.9%, 49.9%) and MI/ACSs (29.8%; 95% CI 5.5%, 54.0%). PM<sub>2.5</sub> and systemic corticosteroid use were independently associated with increases in CTE hospitalisations. We also found evidence of significant additive interactions between the two exposures for HF and MI/ACSs suggesting synergy between these two exposures.

Medical subject headings